Literature DB >> 18688016

Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function.

Dao-Quan Peng1, Gregory Brubaker, Zhiping Wu, Lemin Zheng, Belinda Willard, Michael Kinter, Stanley L Hazen, Jonathan D Smith.   

Abstract

OBJECTIVE: Apolipoprotein A-I (apoAI) acts as an ABCA1-dependent acceptor of cellular phospholipids and cholesterol during the biogenesis of HDL, but this activity is susceptible to oxidative inactivation by myeloperoxidase. We tried to determine which residues mediated this inactivation and create an oxidant-resistant apoAI variant. METHODS AND
RESULTS: Mass spectrometry detected the presence of tryptophan, methionine, tyrosine, and lysine oxidation in apoAI recovered from human atheroma. We investigated the role of these residues in the myeloperoxidase-mediated loss of apoAI activity. Site-directed mutagenesis and chemical modification were used to create variants of apoAI which were tested for ABCA1-dependent cholesterol acceptor activity and oxidative inactivation. We previously reported that tyrosine modification is not required for myeloperoxidase-induced loss of apoAI function. Lysine methylation did not alter the sensitivity of apoAI to myeloperoxidase, whereas site-specific substitution of apoAI methionine to valine increased the sensitivity of apoAI to myeloperoxidase. ApoAI tryptophan residues were identified as essential in apoAI function and oxidant sensitivity as substitution of all four apoAI tryptophan residues to leucine led to loss of function, but the conservative substitution to phenylalanine retained full function and was resistant to oxidative inactivation.
CONCLUSIONS: Tryptophan modification of apoAI is primarily responsible for the myeloperoxidase-mediated loss of the cholesterol acceptor activity of apoAI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688016      PMCID: PMC2610262          DOI: 10.1161/ATVBAHA.108.173815

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  28 in total

Review 1.  Structural models of human apolipoprotein A-I: a critical analysis and review.

Authors:  C G Brouillette; G M Anantharamaiah; J A Engler; D W Borhani
Journal:  Biochim Biophys Acta       Date:  2001-03-30

2.  ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages.

Authors:  J F Oram; R M Lawn; M R Garvin; D P Wade
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

3.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport.

Authors:  Constanze Bergt; Subramaniam Pennathur; Xiaoyun Fu; Jaeman Byun; Kevin O'Brien; Thomas O McDonald; Pragya Singh; G M Anantharamaiah; Alan Chait; John Brunzell; Randolph L Geary; John F Oram; Jay W Heinecke
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

4.  Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1).

Authors:  Maxime Denis; Bassam Haidar; Michel Marcil; Michel Bouvier; Larbi Krimbou; Jacques Genest
Journal:  J Biol Chem       Date:  2003-12-04       Impact factor: 5.157

5.  Lysine residues direct the chlorination of tyrosines in YXXK motifs of apolipoprotein A-I when hypochlorous acid oxidizes high density lipoprotein.

Authors:  Constanze Bergt; Xiaoyun Fu; Nabiha P Huq; Jeff Kao; Jay W Heinecke
Journal:  J Biol Chem       Date:  2003-12-03       Impact factor: 5.157

6.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

Authors:  Lemin Zheng; Benedicta Nukuna; Marie-Luise Brennan; Mingjiang Sun; Marlene Goormastic; Megan Settle; Dave Schmitt; Xiaoming Fu; Leonor Thomson; Paul L Fox; Harry Ischiropoulos; Jonathan D Smith; Michael Kinter; Stanley L Hazen
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

7.  Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.

Authors:  Benjamin J Ansell; Mohamad Navab; Susan Hama; Naeimeh Kamranpour; Gregg Fonarow; Greg Hough; Shirin Rahmani; Rachel Mottahedeh; Ravi Dave; Srinivasa T Reddy; Alan M Fogelman
Journal:  Circulation       Date:  2003-11-24       Impact factor: 29.690

8.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

Authors:  Steven E Nissen; Taro Tsunoda; E Murat Tuzcu; Paul Schoenhagen; Christopher J Cooper; Muhammad Yasin; Gregory M Eaton; Michael A Lauer; W Scott Sheldon; Cindy L Grines; Stephen Halpern; Tim Crowe; James C Blankenship; Richard Kerensky
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

9.  ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I.

Authors:  Jonathan D Smith; Wilfried Le Goff; Megan Settle; Gregory Brubaker; Christine Waelde; Andrew Horwitz; Michael N Oda
Journal:  J Lipid Res       Date:  2004-01-01       Impact factor: 5.922

10.  Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species.

Authors:  Subramaniam Pennathur; Constanze Bergt; Baohai Shao; Jaeman Byun; Sean Y Kassim; Pragya Singh; Pattie S Green; Thomas O McDonald; John Brunzell; Alan Chait; John F Oram; Kevin O'brien; Randolph L Geary; Jay W Heinecke
Journal:  J Biol Chem       Date:  2004-08-02       Impact factor: 5.157

View more
  53 in total

1.  Impact of self-association on function of apolipoprotein A-I.

Authors:  Shobini Jayaraman; Sumiko Abe-Dohmae; Shinji Yokoyama; Giorgio Cavigiolio
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

2.  Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.

Authors:  Jonathan D Smith
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

3.  Tyrosine-lipid peroxide adducts from radical termination: para coupling and intramolecular Diels-Alder cyclization.

Authors:  Roman Shchepin; Matias N Möller; Hye-young H Kim; Duane M Hatch; Silvina Bartesaghi; Balaraman Kalyanaraman; Rafael Radi; Ned A Porter
Journal:  J Am Chem Soc       Date:  2010-11-19       Impact factor: 15.419

4.  Apolipoprotein A-I and cholesterol efflux: the good, the bad, and the modified.

Authors:  Ali Javaheri; Daniel J Rader
Journal:  Circ Res       Date:  2014-05-23       Impact factor: 17.367

5.  Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.

Authors:  Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

6.  HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function.

Authors:  Stela Z Berisha; Greg Brubaker; Takhar Kasumov; Kimberly T Hung; Patricia M DiBello; Ying Huang; Ling Li; Belinda Willard; Katherine A Pollard; Laura E Nagy; Stanley L Hazen; Jonathan D Smith
Journal:  J Lipid Res       Date:  2015-01-05       Impact factor: 5.922

7.  Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.

Authors:  Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

Review 8.  The biology of reactive intermediates in systemic lupus erythematosus.

Authors:  Jim C Oates
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

9.  V-ATPase (Vacuolar ATPase) Activity Required for ABCA1 (ATP-Binding Cassette Protein A1)-Mediated Cholesterol Efflux.

Authors:  Shuhui Wang Lorkowski; Gregory Brubaker; Kailash Gulshan; Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

10.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.